- Nutriband secures new U.S. trademark and international patents for AVERSA(TM) platform
- AVERSA(TM) Fentanyl targets $80M–$200M U.S. sales opportunity as first abuse-deterrent opioid patch
- Strategic sports partnership with Charlotte FC boosts brand visibility and community presence
Strengthening IP for Long-Term Market Protection
Nutriband (NASDAQ: NTRB) continues to solidify its leadership in the development of abuse-deterrent transdermal pharmaceuticals. In February, the company received a trademark registration from the U.S. Patent and Trademark Office (“USPTO”) for “Nutriband(TM),” covering pharmaceutical and product R&D. This comes in addition to a newly granted patent in Macao for its proprietary AVERSA(TM) transdermal system, bringing the total number of countries granting protection to 46.
These intellectual property milestones reflect the growing importance of Nutriband’s AVERSA(TM) platform, which is designed to reduce abuse, diversion, and accidental exposure of potent drugs like fentanyl. With patents now spanning the U.S., Europe, Japan, China (including Hong Kong and Macao), and others, Nutriband is creating an international IP fortress around a potentially game-changing product line.
Commercial Progress Toward FDA Submission
The company’s lead development asset, AVERSA(TM) Fentanyl, represents what could be the first-ever abuse-deterrent transdermal fentanyl patch. Nutriband is working alongside Kindeva Drug Delivery to finalize commercial-scale manufacturing. Kindeva brings expertise in drug-device combination products and has an FDA-approved fentanyl patch platform, enabling efficient integration of AVERSA(TM) technology.
According to Health Advances, AVERSA(TM) Fentanyl could reach peak annual U.S. sales between $80 million and $200 million. These estimates underscore the significant market need for safer opioid delivery systems. With opioid misuse continuing to be a public health crisis, Nutriband’s approach to make transdermal fentanyl less prone to abuse could offer a valuable new tool for clinicians.
Aligning with Market Demand for Safer Therapies
The urgency for pharmaceutical companies to provide abuse-deterrent options is rising. While opioids remain essential for managing chronic and acute pain, the risk of misuse has led to stricter scrutiny from regulators and payers. Transdermal delivery systems offer sustained, controlled dosing, but they are not immune to abuse. AVERSA(TM) tackles this challenge by incorporating aversive agents that make tampering unpleasant or ineffective.
The platform has broader applications beyond fentanyl. It can be adapted for other opioids or stimulants prone to misuse, giving Nutriband a multi-product runway once regulatory clearance is achieved.
Brand Visibility Through Sports Sponsorship
Beyond the lab, Nutriband is working to raise awareness of its technologies and wellness products through a strategic Associate Partnership with Major League Soccer’s Charlotte FC. This relationship aligns well with the company’s regional ties – many Nutriband products, including AI Tape – are manufactured locally at its Pocono Pharmaceutical facility in North Carolina.
The partnership is expected to build brand visibility not only for AI Tape, which targets the athletic market, but also for AVERSA(TM), particularly as the company prepares for broader commercialization and investor outreach.
Outlook: A Biotech with Strong IP and Near-Term Milestones
Nutriband’s continued IP development, clear clinical vision, and strategic manufacturing partnerships set the stage for what could be a transformative year. With regulatory submission for AVERSA(TM) Fentanyl on the horizon, the company offers investors exposure to a differentiated platform in a multibillion-dollar market challenged by abuse risk.
As Nutriband advances toward commercial readiness, it is simultaneously building brand equity and community alignment, both valuable assets in today’s healthcare and consumer environments.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
